The Effectiveness of Probiotics in Reducing Recurrent Vaginal Infections among Women of Reproductive Age

Abstract

Recurrent vaginal infections represent a significant health burden affecting millions of women of reproductive age worldwide. These infections, primarily bacterial vaginosis and vulvovaginal candidiasis, substantially impact quality of life, reproductive health outcomes, and healthcare costs. Traditional antimicrobial treatments often provide only temporary relief, with high recurrence rates prompting investigation of alternative therapeutic approaches. Probiotics, particularly Lactobacillus species, have emerged as promising agents for preventing and treating recurrent vaginal infections by restoring and maintaining healthy vaginal microbiota. This descriptive study examines the effectiveness of probiotic interventions in reducing the frequency and severity of recurrent vaginal infections among women of reproductive age. Through comprehensive analysis of clinical evidence, mechanisms of action, and treatment outcomes, this paper evaluates the role of probiotics as both preventive and therapeutic agents. The findings demonstrate that specific Lactobacillus strains administered orally or intravaginally can significantly reduce recurrence rates of bacterial vaginosis and vulvovaginal candidiasis compared to conventional treatment alone. Probiotics are especially effective when combined with antimicrobials and used for long-term maintenance.  The safety profile of probiotics is favorable, with minimal adverse effects reported across studies. However, variability in probiotic strains, dosing regimens, and administration routes complicates direct comparisons between studies. This comprehensive review supports the integration of evidence-based probiotic protocols into clinical management of recurrent vaginal infections, while identifying areas requiring further investigation to optimize therapeutic outcomes.